Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Puzo Michael J

by · The Markets Daily

Puzo Michael J cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 7.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,749 shares of the medical instruments supplier’s stock after selling 1,416 shares during the period. Puzo Michael J’s holdings in Becton, Dickinson and Company were worth $4,027,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Wesbanco Bank Inc. raised its position in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 48 shares during the period. S.A. Mason LLC lifted its stake in Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after acquiring an additional 50 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Becton, Dickinson and Company by 1.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after acquiring an additional 50 shares during the period. Americana Partners LLC grew its position in Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 52 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its stake in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $278.29.

Read Our Latest Stock Report on Becton, Dickinson and Company

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the transaction, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. This represents a 9.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,984 shares of company stock valued at $1,147,865 over the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 2.1 %

Shares of NYSE BDX opened at $221.59 on Friday. The business has a 50-day moving average of $230.78 and a two-hundred day moving average of $231.51. The company has a market capitalization of $63.63 billion, a price-to-earnings ratio of 36.81, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.88%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company declared that its board has initiated a share buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).